All In Biotech

Drug Trial Radar · NCT02573467

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis

Last checked: Nov 19, 2026Latest source record: Mar 13, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

211

Actual

Start

Nov 2, 2015

Primary completion

Aug 17, 2016

Study completion Feb 13, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 36 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This extension study will provide data to further evaluate the efficacy, safety, and tolerability of three doses of BYM338 and to assess the long-term effects of BYM338 in patients with sporadic inclusion body myositis. The extension study was planned to consist of a Screening epoch (to assess patient eligibility), followed by a Treatment Period 1 epoch (double-blind and placebo-controlled), and a Treatment Period 2 epoch (open-label). A Post-treatment Follow-up (FUP) epoch was also planned for patients who discontinued prematurely. Patients who complete the core study and qualify for this extension study entered Treatment Period 1 and continued on the study drug to which they were randomized in the core study (either to one of the three bimagrumab doses (1 mg/kg, 3 mg/kg, and 10mg/kg) or placebo) during Treatment Period 1. Thus, Treatment Period 1 was double-blind and placebo-controlled. Participants were to continue in Treatment Period 1 until the dose with the best benefit-risk profile was determined from the core study data and selected (duration of Treatment Period 1 was estimated to be between 6 and 8 months). Once the dose with the best benefit-risk profile was selected, all participants (including those who were receiving placebo) were planned to enter Treatment Period 2 and switch to open-label treatment with bimagrumab at the selected dose. The core study has been completed but since the core study did not meet the primary end point (no bimagrumab dose was identified based on the core study efficacy results) the extension study was terminated as per protocol/sponsor's decision; therefore, no patients had entered Treatment Period 2. Instead, all patients were to return for the End of Treatment Period 1 (EOT1) visit at their next scheduled visit. As per protocol, all patients who discontinued study medication during Treatment Period 1 for any reason, including due to the study having been stopped as per protocol/sponsor's decision, were to have entered and complete the 6-month FUP after their EOT1 visit. Due to the nature of the design of the core and extension studies and termination of study medication in the extension study, the treatment duration for individual patients varied considerably. Consequently, the number of patients contributing data to the efficacy analyses at Week 104 and later timepoints was decreased.

Conditions

  • Sporadic Inclusion Body Myositis

Interventions

  • BimagrumabDrug

    BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.

  • PlaceboDrug

    Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths.Time frame: to end of study (up to 14 months, including the 6-month treatment-free follow-up period)
  2. Change From Core Study Baseline in 6 Minute Walking Distance Test (6MWD)Time frame: Core study baseline, weeks 52, 78, 104, and >=117

Locations

38 sites in 10 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Orange, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Kansas City, Kansas

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Columbus, Ohio

  • Novartis Investigative Site

    Portland, Oregon

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    St Leonards, New South Wales, Australia

  • Novartis Investigative Site

    Cauldfield, Victoria, Australia

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Edegem, Antwerpen, Belgium

  • Novartis Investigative Site

    Copenhagen, Denmark

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Brescia, BS, Italy

  • Novartis Investigative Site

    Rome, Lazio, Italy

  • Novartis Investigative Site

    Messina, ME, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Padova, PD, Italy

  • Novartis Investigative Site

    Tokushima, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site

    Kumamoto, Kumamoto, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, Japan

  • Novartis Investigative Site

    Osaka, Osaka, Japan

  • Novartis Investigative Site

    Kodaira, Tokyo, Japan

  • Novartis Investigative Site

    Wakayama, Wakayama, Japan

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Leiden, Netherlands

  • Novartis Investigative Site

    Zurich, Switzerland

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    Newcastle upon Tyne, United Kingdom

  • Novartis Investigative Site

    Salford, Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.